A compensatory role of NF-κB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Endo, Fumitaka ^a   Nishizuka, Satoshi S ^a   Kume, Kohei ^a   Ishida, Kazushige ^a   Katagiri, Hirokatsu ^a   Ishida, Kaoru ^a   Sato, Kei ^a   Iwaya, Takeshi ^a   Koeda, Keisuke ^a   Wakabayashi, Go ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROLINE; PROTEIN P53; TRANSCRIPTION FACTOR RELA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CODON; EXON; GENETIC CODE; HOMOZYGOSITY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; STOMACH CANCER; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CODON; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; NF-KAPPA B; PROTEIN BINDING; PROTEIN TRANSPORT; STOMACH NEOPLASMS; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896337308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090155     Document Type: Article

References (56)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, et al. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820. (Pubitemid 350044801)
3. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, et al. (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29: 4387-4393.
4. Matsuo T, Nishizuka SS, Ishida K, Endo F, Katagiri H, et al. (2013) Evaluation of chemosensitivity prediction using quantitative dose-response curve classification for highly advanced/relapsed gastric cancer. World J Surg Oncol 11: 11.
5. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, et al. (2003) Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100: 14229-14234. (Pubitemid 37499219)
6. Spurrier B, Ramalingam S, Nishizuka S (2008) Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 3: 1796-1808.
7. Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, et al. (2003) Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 63: 5243-5250. (Pubitemid 37139837)
8. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Jr., et al. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349. (Pubitemid 27051604)
9. Ishida K, Nishizuka SS, Chiba T, Ikeda M, Kume K, et al. (2012) Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers. PLoS One 7: e43236.
10. Chang CT, Ho TY, Lin H, Liang JA, Huang HC, et al. (2012) 5-Fluorouracil induced intestinal mucositis via nuclear factor-kappaB activation by transcriptomic analysis and in vivo bioluminescence imaging. PLoS One 7: e31808.
11. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E (2004) Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res 64: 8167-8176. (Pubitemid 39491752)
12. Vilgelm AE, Washington MK, Wei J, Chen H, Prassolov VS, et al. (2010) Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Mol Cancer Ther 9: 693-705.
13. Nishizuka S, Ramalingam S, Spurrier B, Washburn FL, Krishna R, et al. (2008) Quantitative protein network monitoring in response to DNA damage. J Proteome Res 7: 803-808. (Pubitemid 351294044)
14. Nishizuka S, Winokur ST, Simon M, Martin J, Tsujimoto H, et al. (2001) Oligonucleotide microarray expression analysis of genes whose expression is correlated with tumorigenic and non-tumorigenic phenotype of HeLa x human fibroblast hybrid cells. Cancer Lett 165: 201-209. (Pubitemid 32244178)
15. Kimura Y, Oda S, Egashira A, Kakeji Y, Baba H, et al. (2004) A variant form of hMTH1, a human homologue of the E coli mutT gene, correlates with somatic mutation in the p53 tumour suppressor gene in gastric cancer patients. J Med Genet 41: e57.
16. Kusser WC, Levin DB, Glickman BW (1993) Sensitive two-stage PCR of p53 genomic DNA exons 5-9. PCR Methods Appl 2: 250-252. (Pubitemid 23159568)
17. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739.
18. Aliouat-Denis CM, Dendouga N, Van den Wyngaert I, Goehlmann H, Steller U, et al. (2005) p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2. Mol Cancer Res 3: 627-634. (Pubitemid 41780918)
19. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, et al. (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120. (Pubitemid 44040989)
20. Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-694. (Pubitemid 32706359)
21. Rouault JP, Prevot D, Berthet C, Birot AM, Billaud M, et al. (1998) Interaction of BTG1 and p53-regulated BTG2 gene products with mCaf1, the murine homolog of a component of the yeast CCR4 transcriptional regulatory complex. J Biol Chem 273: 22563-22569. (Pubitemid 28399824)
22. Zhang Y, Qian Y, Lu W, Chen X (2009) The G protein-coupled receptor 87 is necessary for p53-dependent cell survival in response to genotoxic stress. Cancer Res 69: 6049-6056.
23. Portales-Casamar E, Thongjuea S, Kwon AT, Arenillas D, Zhao X, et al. (2010) JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles. Nucleic Acids Res 38: D105-110.
24. Ju J, Schmitz JC, Song B, Kudo K, Chu E (2007) Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. Clin Cancer Res 13: 4245-4251. (Pubitemid 47105989)
25. Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokota J, et al. (1991) p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 51: 5800-5805.
26. Perkins ND (2012) The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 12: 121-132.
27. Baldwin AS (2012) Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer. Immunol Rev 246: 327-345.
28. Goetz CA, Baldwin AS (2008) NF-κB pathways in the immune system: control of the germinal center reaction. Immunol Res 41: 233-247.
29. Karin M, Greten FR (2005) NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759. (Pubitemid 41400849)
30. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309. (Pubitemid 40488635)
31. DiDonato JA, Mercurio F, Karin M (2012) NF-κkB and the link between inflammation and cancer. Immunol Rev 246: 379-400.
32. Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, et al. (2003) Inhibition of inducible NF-κB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 289: 27-35. (Pubitemid 36993834)
33. Bohuslav J, Chen LF, Kwon H, Mu Y, Greene WC (2004) p53 induces NF-κB activation by an IκB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 279: 26115-26125. (Pubitemid 38798756)
34. Ryan KM, Ernst MK, Rice NR, Vousden KH (2000) Role of NF-κB in p53-mediated programmed cell death. Nature 404: 892-897. (Pubitemid 30230343)
35. Schumm K, Rocha S, Caamano J, Perkins ND (2006) Regulation of p53 tumour suppressor target gene expression by the p52 NF-κB subunit. EMBO J 25: 4820-4832. (Pubitemid 44607027)
36. Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, et al. (2007) Mutant p53 enhances nuclear factor κB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 67: 2396-2401. (Pubitemid 46548921)
37. Wu H, Lozano G (1994) NF-κB activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem 269: 20067-20074.
38. Schneider G, Kramer OH (2011) NFκB/p53 crosstalk-a promising new therapeutic target. Biochim Biophys Acta 1815: 90-103.
39. Barre B, Perkins ND (2010) The Skp2 promoter integrates signaling through the NF-κB, p53, and Akt/GSK3beta pathways to regulate autophagy and apoptosis. Mol Cell 38: 524-538.
40. Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, et al. (2011) The codon 72 polymorphism of p53 regulates interaction with NF-κB and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 31: 1201-1213.
41. Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, et al. (2010) Cross talk between stimulated NF-κB and the tumor suppressor p53. Oncogene 29: 2795-2806.
42. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A (2003) TP53 and gastric carcinoma: a review. Hum Mutat 21: 258-270. (Pubitemid 36292967)
43. Cattelani S, Ferrari-Amorotti G, Galavotti S, Defferrari R, Tanno B, et al. (2012) The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform. Neoplasia 14: 634-643.
44. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107.
45. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, et al. (2007) P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 121: 1481-1486. (Pubitemid 47328706)
46. Kuroda Y, Nakao H, Ikemura K, Katoh T (2007) Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis. Oral Oncol 43: 1043-1048. (Pubitemid 47532782)
47. Godai TI, Suda T, Sugano N, Tsuchida K, Shiozawa M, et al. (2009) Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer 9: 420.
48. Proestling K, Hebar A, Pruckner N, Marton E, Vinatzer U, et al. (2012) The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. PLoS One 7: e47325.
49. Huang ZH, Hua D, Li LH, Zhu JD (2008) Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. J Cancer Res Clin Oncol 134: 1129-1134.
50. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365. (Pubitemid 36278852)
51. Mantovani F, Tocco F, Girardini J, Smith P, Gasco M, et al. (2007) The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol 14: 912-920. (Pubitemid 47525182)
52. Sakiyama T, Kohno T, Mimaki S, Ohta T, Yanagitani N, et al. (2005) Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer 114: 730-737. (Pubitemid 40344434)
53. Francisco G, Menezes PR, Eluf-Neto J, Chammas R (2011) Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer 129: 920-930.
54. Santos AM, Sousa H, Portela C, Pereira D, Pinto D, et al. (2006) TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 340: 256-262. (Pubitemid 41827674)
55. Xu Y, Yao L, Ouyang T, Li J, Wang T, et al. (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11: 7328-7333. (Pubitemid 41507691)
56. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, et al. (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11: 5098-5103. (Pubitemid 41003693)